Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Nephrology · Hypertensive Nephrosclerosis

Tracking Your Progress: Monitoring and Future Risk

At a Glance

For hypertensive nephrosclerosis, future kidney failure risk depends mainly on current eGFR, urine protein measured by UACR, and how quickly eGFR changes. The KFRE combines these results with age and sex to estimate 2- or 5-year risk and guide monitoring.

Living with hypertensive nephrosclerosis often feels like living under a microscope. Between the blood draws, urine samples, and daily blood pressure checks, the constant monitoring can be emotionally draining. However, this data is exactly what allows you and your doctor to move from “guessing” to “knowing” your risk. Your prognosis is not a single number; it is a story told by the trends in your lab results over time [1][2].

The Two Most Important Numbers

Your risk of progressing to kidney failure is primarily determined by two variables, which doctors use to “stratify” your risk:

  1. eGFR (The Filter Rate): This tells you how much work your kidneys are currently doing, and it is categorized into stages G1 through G5. A lower eGFR generally means more advanced disease [3].
  2. UACR (The Protein Leak): This is often more important for predicting the future than the eGFR. High levels of protein in the urine (categories A1, A2, A3) increase the risk of faster scarring. If your eGFR is low but your protein is also low, your risk is lower than if you had heavy protein leakage, though low eGFR itself still carries significant risks [1][4].

Understanding Your “Slope”

Doctors don’t just look at where your eGFR is today; they look at its slope—the speed at which it is changing.

  • Stable Progression: A loss of less than 1 to 2 mL/min/1.73 m² per year may occur with stable, well-managed disease [5].
  • Fast Progression: A sustained decline of about 5 mL/min/1.73 m² per year or more is generally considered rapid progression [6][7].

If you see a sudden, severe drop, contact your care team promptly. A sudden fall in eGFR should be evaluated for acute kidney injury (from dehydration, infection, NSAIDs, or other causes) rather than waiting months for the next routine check [5][8].

The Kidney Failure Risk Equation (KFRE)

One of the most powerful tools available today is the KFRE. This formula uses your age, sex, eGFR, and UACR to estimate the probability that you will require dialysis or a transplant within the next 2 or 5 years. It is an estimate validated mainly for stable CKD in the eGFR G3–G5 range [9].

  • Low Risk (under 3–5%): Typically managed by a primary doctor or regular nephrologist visits [10].
  • Higher Risk (over 10–20%): May trigger a referral to a specialized multidisciplinary kidney clinic, though referral practices vary locally [11].
  • Advanced Risk (over 40%): This is the threshold where doctors usually begin “modality education”—talking seriously about transplant or dialysis options so you are prepared for the future [12].

Your Monitoring Schedule

How often you need testing depends on your “risk category” based on your eGFR and UACR stages, as well as your medications (often visualized by doctors as a green, yellow, orange, or red “heat map”) [13]. The table below is an example; your schedule must be individualized by your care team.

Risk Level eGFR & UACR Frequency Potassium/Creatinine Check
Stable/Low Risk (e.g., G1/A1) Every 6–12 months [13] Annually [13]
Moderate Risk Every 3–6 months [13] Every 6 months
High/Very High Risk (e.g., G4/A3) Every 1–3 months [13] Every 1–3 months
Medication Change N/A Within 1–4 weeks of change [8]

Managing the Psychological Toll

It is normal to feel “scanxiety”—the anxiety that peaks just before your lab results are released. To manage this:

  • Focus on the Trend: One “off” reading is a data point, not a destiny. Look at your results over the last year, not just the last month [14].
  • Own Your Data: Keep a folder or app with your KFRE scores and eGFR slope so you can see the impact of your hard work in managing your blood pressure [15].
  • Ask for Context: If you see a number that scares you, call your nurse or doctor. Often, there is a simple biological explanation (like a temporary dip from a new blood pressure pill) that is actually a sign of long-term protection, but sometimes it requires evaluation [16].

Common questions in this guide

How do eGFR and UACR affect my kidney failure risk?
eGFR estimates how well your kidneys filter blood, while UACR measures protein leaking into your urine. A lower eGFR and higher UACR generally indicate greater risk, although the combination and the trend over time matter. Someone with low eGFR but little urine protein may have a different risk from someone with the same eGFR and heavy protein leakage.
What counts as a fast decline in eGFR?
A sustained eGFR decline of about 5 mL/min/1.73 m² per year or more is generally considered rapid progression. A sudden severe drop should be reported promptly because dehydration, infection, certain pain relievers called NSAIDs, or another cause of acute kidney injury may be reversible.
What does a KFRE score tell me?
The Kidney Failure Risk Equation, or KFRE, combines age, sex, eGFR, and UACR to estimate the chance of needing dialysis or a kidney transplant within two or five years. It is an estimate rather than a certainty and is used mainly for people with stable chronic kidney disease in stages G3 through G5.
How often should I have kidney function and electrolyte tests?
The schedule depends on your eGFR and UACR risk category and any medication changes. Lower-risk disease may be checked every 6–12 months, moderate risk every 3–6 months, and high or very high risk every 1–3 months; potassium and creatinine are often checked within 1–4 weeks after a medication change. Your care team should set the schedule for you.
When should I ask about dialysis or transplant education?
A KFRE estimate above about 10–20% may prompt referral to a specialized kidney clinic, although practices vary. At around 40% or higher, clinicians often begin education about dialysis or transplant so planning can start early.
How can I cope with anxiety about frequent kidney tests?
Try to focus on your results over time rather than one reading, and keep a record of your eGFR trend, UACR, blood pressure, and KFRE scores. If a result worries you, ask your nurse or doctor for context, because temporary changes can have explanations but sometimes need prompt evaluation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current Kidney Failure Risk Equation (KFRE) score for the next 2 and 5 years?
  2. 2.Is my kidney function (eGFR) declining at a rate you consider 'fast,' and how does my 'slope' compare to previous years?
  3. 3.How much does my current level of protein in the urine (UACR) increase my risk compared to my blood pressure alone?
  4. 4.Given my current risk score, should we be discussing a referral for transplant evaluation or dialysis education now?
  5. 5.Based on my medications, how frequently do you want me to get my potassium and creatinine levels checked?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Effect of Proteinuria and Glomerular Filtration Rate on Renal Outcome in Patients with Biopsy-Proven Benign Nephrosclerosis.

    Sumida K, Hoshino J, Ueno T, et al.

    PloS one 2016; (11(1)):e0147690 doi:10.1371/journal.pone.0147690.

    PMID: 26809068
  2. 2

    Time-averaged proteinuria during follow-up and renal prognosis in patients with biopsy-proven benign nephrosclerosis.

    Amano H, Koike K, Haruhara K, et al.

    Clinical and experimental nephrology 2020; (24(8)):688-695 doi:10.1007/s10157-020-01885-w.

    PMID: 32274596
  3. 3

    Clinicopathological predictors for progression of chronic kidney disease in nephrosclerosis: a biopsy-based cohort study.

    Yamanouchi M, Hoshino J, Ubara Y, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019; (34(7)):1182-1188 doi:10.1093/ndt/gfy121.

    PMID: 29788462
  4. 4

    Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes.

    Nichols GA, Déruaz-Luyet A, Brodovicz KG, et al.

    BMC nephrology 2020; (21(1)):167 doi:10.1186/s12882-020-01792-y.

    PMID: 32380961
  5. 5

    The prevalence of chronic kidney disease in Iceland according to KDIGO criteria and age-adapted estimated glomerular filtration rate thresholds.

    Jonsson AJ, Lund SH, Eriksen BO, et al.

    Kidney international 2020; (98(5)):1286-1295 doi:10.1016/j.kint.2020.06.017.

    PMID: 32622831
  6. 6

    Geographic Variation and US County Characteristics Associated With Rapid Kidney Function Decline.

    Bowe B, Xie Y, Xian H, et al.

    Kidney international reports 2017; (2(1)):5-17 doi:10.1016/j.ekir.2016.08.016.

    PMID: 29142937
  7. 7

    Dynamic Bayesian networks to predict loss of kidney function: a cross-institution use case in a large cohort with or at-risk of CKD.

    Petousis P, Gordon D, Duru OK, et al.

    BMC medical informatics and decision making 2026; (26(1)).

    PMID: 42163261
  8. 8

    Acute Estimated Glomerular Filtration Rate Decline After Initiation of Therapies That Slow Kidney Disease Progression: Clinical Practice Implications.

    Cherney DZI, Alicic RZ, Bonaca MP

    Mayo Clinic proceedings 2026; (101(8)):1347-1366 doi:10.1016/j.mayocp.2026.01.010.

    PMID: 42017862
  9. 9

    Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis.

    Tangri N, Grams ME, Levey AS, et al.

    JAMA 2016; (315(2)):164-74 doi:10.1001/jama.2015.18202.

    PMID: 26757465
  10. 10

    Risk-based referral model to nephrologist specialist care in Stockholm.

    Caldinelli A, Faucon AL, Sjölander A, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2025; (41(1)):102-111 doi:10.1093/ndt/gfaf128.

    PMID: 40632493
  11. 11

    Evaluation of Kidney Failure Risk Equation score for vascular access planning in an Australian cohort.

    Hong R, Hirsch D, Li K, et al.

    Internal medicine journal 2026; (56(3)):364-372 doi:10.1111/imj.70281.

    PMID: 41451789
  12. 12

    Clinical impact of the Kidney Failure Risk Equation for vascular access planning.

    Hahn Lundström U, Ramspek CL, Dekker FW, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024; (39(12)):2079-2087 doi:10.1093/ndt/gfae064.

    PMID: 38486367
  13. 13

    Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.

    Shubrook JH, Neumiller JJ, Wright E

    Postgraduate medicine 2022; (134(4)):376-387 doi:10.1080/00325481.2021.2009726.

    PMID: 34817311
  14. 14

    Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective Cohort.

    Heerspink H, Nolan S, Carrero JJ, et al.

    Advances in therapy 2024; (41(8)):3264-3277 doi:10.1007/s12325-024-02913-x.

    PMID: 38958839
  15. 15

    A primary care guide to the screening and pharmacologic management of chronic kidney disease in people living with type 2 diabetes.

    Wright EE, Cebrian A, Ngui D

    Primary care diabetes 2025; (19(5)):411-421 doi:10.1016/j.pcd.2025.05.005.

    PMID: 40903105
  16. 16

    Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.

    Agarwal R, Correa-Rotter R, Navaneethan SD, et al.

    Journal of the American Society of Nephrology : JASN 2026; doi:10.1681/ASN.0000001071.

    PMID: 41905767

This page is for informational purposes only and does not constitute medical advice about hypertensive nephrosclerosis. Your clinician or nephrologist should interpret your results and set your monitoring schedule.

Get notified when new evidence is published on nephrosclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.